A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer-Reference-Cited by-全球学者库

登录注册会员服务联系我们

A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer

Published:2017-04-04 Issue:5 Volume:6 Page:953-961
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Chen Gang¹²³^ORCID,Chen Xi¹²³,Zhang Yaxiong¹²³,Yan Fang¹²³⁴,Fang Wenfeng¹²³,Yang Yunpeng¹²³,Hong Shaodong¹²³^ORCID,Miao Siyu¹²³⁵,Wu Manli¹²³⁵,Huang Xiaodan¹²³⁵,Luo Youli¹²³⁶,Zhou Cong¹²³⁶,Gong Run¹²³⁶,Huang Yan¹²³,Zhou Ningning¹²³,Zhao Hongyun¹²³,Zhang Li¹²³

Affiliation:

1. Department of Medical Oncology; Sun Yat-sen University Cancer Center; Guangzhou China

2. State Key Laboratory of Oncology in South China; Guangzhou China

3. Collaborative Innovation Center for Cancer Medicine; Guangzhou China

4. Department of Anesthesiology; Sun Yat-sen University Cancer Center; Guangzhou China

5. Zhongshan School of Medicine; Sun Yat-sen University; Guangzhou China

6. Department of Medical Oncology; the Fifth Affiliated Hospital of Sun Yat-Sen University; Zhu Hai China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference35 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J. Clin.,2014

2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010

4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

5. Ceritinib in ALK-rearranged non-small-cell lung cancer;Shaw;N. Engl. J. Med.,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?;Journal of Cancer Research and Clinical Oncology;2023-07-22

2. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences;Critical Reviews in Oncology/Hematology;2022-12

3. Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Oncology and Therapy;2021-06-11

4. Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion;Translational Lung Cancer Research;2020-08

5. Metastasis Patterns and Prognosis of Octogenarians with NSCLC: A Population-based Study;Aging and disease;2020

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前全球学者库共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3